CollPlant Biotechnologies Ltd (CLGN) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of CollPlant Biotechnologies Ltd $1.08, price $3.46, upside -68.8%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range $2.73 – $224.80 · fair‑value band $0.7100 – $1.35 · the $3.46 price screens above the $1.08 fair value. Dashed = 300-day average. As of Oct 4, 2026.
Follow CollPlant Biotechnologies in your weekly email
Every Wednesday you see whether CollPlant Biotechnologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology.
Show more
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Stock analysis
CollPlant Biotechnologies Ltd (CLGN) currently trades at $3.46, while our model-based Fair Value estimate is $1.08, 68.8% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $0.7100 (bear) to $1.35 (bull), the price of $3.46 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
CollPlant Biotechnologies Ltd reported revenue of $2.4M in FY2025 versus $15.6M in FY2021, a compound −37.6%/yr. Reported net income was −$11.5M in FY2025.
Key figures
Market cap $6.5M · P/S ratio 20.6 · EPS (TTM) $−9.50 · Return on equity −162% · Return on assets (EBIT) −53.2% · Operating margin −2,438% · Revenue growth (YoY) −39.7% · Free cash flow −$9.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 86% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −69%, CLGN screens richer than that median.
Fair Value models
Bear $0.7100Fair Value $1.08Bull $1.35
Price $3.46 · Upside -68.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−17.3%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.6%
’16
’17
’18
’19
’20
’21
’23
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−91.2% (2020) → −484.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare CollPlant Biotechnologies Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 607 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score52 · Above median
Fair Value upside−68.8% · Below median
Profitability
Return on assets−63.0% · Bottom 25%
Growth and dividend
Revenue growth−39.7% · Bottom 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.08× · Cheaper than median
P/S (TTM)20.57× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is CollPlant Biotechnologies Ltd (CLGN) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of $1.08 versus a price of $3.46, about −69% upside (overvalued).
What is the fair value of CLGN?
Our model-based fair value for CollPlant Biotechnologies Ltd is $1.08 (as of Oct 4, 2026), built from audited fundamentals. The current price: $3.46.
What is the quality score of CLGN?
CollPlant Biotechnologies Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CollPlant Biotechnologies Ltd (CLGN)?
Our model-based price target is the fair value of $1.08 (as of Oct 4, 2026) from 1 valuation models. Cautious scenario $0.7100, optimistic scenario $1.35. It is a calculation from audited fundamentals, not an analyst target.
What is the CollPlant Biotechnologies Ltd stock forecast for 2026?
Our models put fair value at $1.08, about −69% upside versus a price of $3.46 (overvalued). Cautious scenario $0.7100, optimistic scenario $1.35. The calculation is refreshed regularly with new filings.
What is the intrinsic value of CollPlant Biotechnologies Ltd (CLGN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CollPlant Biotechnologies Ltd it is $1.08 per share (as of Oct 4, 2026), against a price of $3.46. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is CollPlant Biotechnologies Ltd stock overvalued or undervalued in 2026?
As of Oct 4, 2026, CLGN trades above its calculated fair value: price $3.46, fair value $1.08, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CLGN?
No. The price is what the market pays today ($3.46); the fair value is what the company's own numbers justify ($1.08). For CollPlant Biotechnologies Ltd the two are $2.38 per share apart. That gap is exactly why we show both numbers side by side.
How much is CollPlant Biotechnologies Ltd worth?
The market values CollPlant Biotechnologies Ltd at about $6.5M (market capitalisation, as of Oct 4, 2026). Per share that is $3.46; our models calculate a fair value of $1.08 per share.
What do the bullish and bearish scenarios say about CLGN?
Our models span a range for CollPlant Biotechnologies Ltd: cautious scenario $0.7100, base $1.08, optimistic $1.35 per share (as of Oct 4, 2026, price $3.46). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CollPlant Biotechnologies Ltd (CLGN)?
Balance-sheet figures for CollPlant Biotechnologies Ltd (as of Oct 4, 2026): return on equity −162.0%, debt of 0.00 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is CLGN from its 52-week high?
CollPlant Biotechnologies Ltd trades at $3.46, about 86% below its 52-week high of $24.90 and 27% above the low of $2.73 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $1.08 is for.
Which stocks are comparable to CollPlant Biotechnologies Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CollPlant Biotechnologies Ltd stock attractive at the current price?
The data as of Oct 4, 2026: price $3.46, calculated fair value $1.08 (−69%), Quality Score 52/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CLGN calculated?
We run CollPlant Biotechnologies Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.08, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. CollPlant Biotechnologies Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CollPlant Biotechnologies Ltd (CLGN)?
The closing price on Oct 2, 2026 was $3.46. Our model-based fair value is $1.08, about −69% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CollPlant Biotechnologies Ltd right now?
The price sits above even our optimistic bull case ($1.35). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($0.7100 to $1.35) leaves room in how you read the outcome.
Key figures of CollPlant Biotechnologies Ltd
How large is the market capitalisation of CollPlant Biotechnologies Ltd (CLGN)?
The market capitalisation of CollPlant Biotechnologies Ltd is $6.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CollPlant Biotechnologies Ltd (CLGN)?
The price-to-sales ratio of CollPlant Biotechnologies Ltd is 20.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CollPlant Biotechnologies Ltd (CLGN)?
Earnings per share at CollPlant Biotechnologies Ltd are $−9.50. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of CollPlant Biotechnologies Ltd (CLGN)?
The return on equity (ROE) of CollPlant Biotechnologies Ltd is −162% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CollPlant Biotechnologies Ltd (CLGN)?
On an EBIT basis the return on assets of CollPlant Biotechnologies Ltd is −53.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CollPlant Biotechnologies Ltd (CLGN)?
The operating margin of CollPlant Biotechnologies Ltd is −2,438% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CollPlant Biotechnologies Ltd (CLGN)?
Revenue at CollPlant Biotechnologies Ltd is growing −39.7% versus a year earlier (3y avg +99.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CollPlant Biotechnologies Ltd (CLGN) generate?
The free cash flow of CollPlant Biotechnologies Ltd is −$9.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does CollPlant Biotechnologies Ltd (CLGN) hold?
CollPlant Biotechnologies Ltd holds more cash than debt, $3.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch CollPlant Biotechnologies Ltd in the live analysis
One click puts CollPlant Biotechnologies Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Oct 4, 2026